Sanofi's Lantus XR gets first approval in Asia

Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for insulin glargine [rDNA origin] injection from French drug major Sanofi (Euronext: SAN).

Known as Toujeo in the USA and Europe, the new insulin treatment will be available in Japan under the trade name Lantus XR. Pierre Chancel, senior vice president, head of global diabetes, Sanofi, said: "In just four months, Sanofi's next generation basal insulin has been granted marketing authorization by three major regulatory authorities. This first approval in Asia adds to the momentum of an active launch year, and it highlights our commitment to improving diabetes care worldwide."

Clinical backing